[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Jimbo H, Kamata S, Miura K, Asamoto S, Tada S, Endo T, Masubuchi T, Nakamura N, Fushimi C: Operative management of skull base malignant tumors arising from the nasal cavity and paranasal sinus: recent strategies used in 25 cases. Neurol Med Chir (Tokyo); 2010 Jan;50(1):20-6; discussion 26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Operative management of skull base malignant tumors arising from the nasal cavity and paranasal sinus: recent strategies used in 25 cases.
  • Cancers of the paranasal sinuses and nasal cavity are the most common malignant tumors of the anterior and anterolateral skull base.
  • The treatment of these tumors affecting the skull base is complex due to the significant anatomical features.
  • En bloc resections using anterior skull base resection, orbital resection, middle fossa resection, and combined procedures of these three resections were performed.
  • Using a combination of adjuvant radiation and chemotherapy, we have achieved a 2-year disease-free survival rate of 90% in these cases.
  • We believe that the optimal management of such malignant tumors involves a multimodal and multidisciplinary team approach.
  • Here we present our recent institutional experience and treatment policy employed during the past 3 years.
  • [MeSH-major] Neurosurgical Procedures / methods. Nose Neoplasms / surgery. Paranasal Sinus Neoplasms / surgery. Skull Base / pathology. Skull Base / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Cranial Fossa, Middle / anatomy & histology. Cranial Fossa, Middle / pathology. Cranial Fossa, Middle / surgery. Drug Therapy / methods. Drug Therapy / statistics & numerical data. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Orbit / anatomy & histology. Orbit / pathology. Orbit / surgery. Osteotomy / contraindications. Osteotomy / methods. Paranasal Sinuses / anatomy & histology. Paranasal Sinuses / pathology. Paranasal Sinuses / surgery. Patient Care Team. Postoperative Complications / etiology. Postoperative Complications / physiopathology. Postoperative Complications / prevention & control. Radiotherapy, Adjuvant / methods. Radiotherapy, Adjuvant / statistics & numerical data. Reconstructive Surgical Procedures / methods. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098020.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Ochiai H, Kawano H, Miyaoka R, Kawano N, Shimao Y, Kawasaki K: Primary diffuse large B-cell lymphomas of the temporoparietal dura mater and scalp without intervening skull bone invasion. Neurol Med Chir (Tokyo); 2010;50(7):595-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary diffuse large B-cell lymphomas of the temporoparietal dura mater and scalp without intervening skull bone invasion.
  • Magnetic resonance imaging and computed tomography revealed a solid homogeneously enhanced mass in the left temporoparietal scalp, and an extra-axial intracranial mass that existed just below the scalp without intervening skull invasion.
  • The patient received whole-brain radiation therapy, and subsequent chemotherapy with cyclophosphamide, adriamycin, vincristine, and prednisolone.
  • The present case of DLBCLs in the scalp and dura without intervening skull bone invasion indicates that malignant lymphoma should be considered in the differential diagnosis of scalp and dural tumors without intervening skull bone invasion.
  • [MeSH-major] Dura Mater / surgery. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / surgery. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / surgery. Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / surgery. Scalp / surgery. Skin Neoplasms / diagnosis. Skin Neoplasms / surgery. Tomography, X-Ray Computed
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Combined Modality Therapy. Cranial Irradiation. Craniotomy. Humans. Male. Neoplasm Invasiveness. Parietal Bone. Radiotherapy, Adjuvant. Temporal Bone


3. Tan C, Barrington S, Rankin S, Landau D, Pilling J, Spicer J, Cane P, Lang-Lazdunski L: Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma. J Thorac Oncol; 2010 Mar;5(3):385-8
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma.
  • INTRODUCTION: To investigate the role of 18-fluorodeoxyglucose positron emission tomography-computed tomography (18-FDG-PET-CT) in the surveillance of patients after multimodality treatment of malignant pleural mesothelioma.
  • METHODS: Retrospective study of patients who had chemotherapy, radical surgery, extrapleural pneumonectomy or pleurectomy/decortication, and radiotherapy for mesothelioma in our unit.
  • PET-CT was performed after multimodality therapy to evaluate response to treatment or when disease recurrence was suspected.
  • 18-FDG-PET scans were acquired from skull base to upper thigh with low-dose CT scans for attenuation correction and image fusion.
  • Twenty-five patients had PET-CT performed after multimodality therapy.
  • This was performed in 11 patients in whom disease recurrence was suspected at a median of 9 (range, 6-16) months after treatment.
  • Surveillance PET-CT was performed in 14 asymptomatic patients at a median of 11 (range, 7-13) months after treatment.
  • CONCLUSIONS: 18-FDG-PET-CT is useful in diagnosing disease recurrence after multimodality therapy for malignant pleural mesothelioma.
  • [MeSH-major] Fluorodeoxyglucose F18. Mesothelioma / radiography. Mesothelioma / radionuclide imaging. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / radiography. Neoplasm Recurrence, Local / radionuclide imaging. Neoplasm Recurrence, Local / therapy. Pleural Neoplasms / radiography. Pleural Neoplasms / radionuclide imaging. Pleural Neoplasms / therapy. Population Surveillance. Radiopharmaceuticals. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087231.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


Advertisement
4. Ganly I, Patel SG, Singh B, Kraus DH, Bridger PG, Cantu G, Cheesman A, De Sa G, Donald P, Fliss DM, Gullane P, Janecka I, Kamata SE, Kowalski LP, Levine PA, Medina dos Santos LR, Pradhan S, Schramm V, Snyderman C, Wei WI, Shah JP: Craniofacial resection for malignant melanoma of the skull base: report of an international collaborative study. Arch Otolaryngol Head Neck Surg; 2006 Jan;132(1):73-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Craniofacial resection for malignant melanoma of the skull base: report of an international collaborative study.
  • OBJECTIVE: To report postoperative mortality, complications, and outcomes in a subset of patients with the histologic diagnosis of malignant melanoma extracted from an existing database of a large cohort of patients accumulated from multiple institutions.
  • SETTING: Seventeen international tertiary referral centers performing craniofacial surgery for malignant skull base tumors.
  • PATIENTS: A total of 53 patients were identified from a database of 1307 patients who had craniofacial resection for malignant tumors at 17 institutions.
  • Of the 53 patients, 25 (47%) had had prior single modality or combined treatment, which included surgery in 22 (42%), radiation in 11 (21%), and chemotherapy in 2 (4%).
  • Adjuvant radiotherapy was given in 22 (42%), chemotherapy in 3 (6%), and vaccine or interferon therapy in 2 (4%).
  • The extent of orbital involvement and adjuvant postoperative radiation therapy (PORT) were independent predictors of DSS and OS on multivariate analysis, whereas only PORT was an independent predictor of RFS.
  • CONCLUSIONS: Craniofacial resection in patients with malignant melanoma of the skull base has mortality (6%) and complication rates (26%) comparable to other malignant tumors of the skull base.
  • However, malignant melanoma is associated with a much poorer OS, DSS, and RFS.
  • These factors must be taken into account when considering craniofacial resection in a patient with malignant melanoma invading the skull base.
  • [MeSH-major] Cranial Fossa, Anterior / surgery. Facial Bones / surgery. Melanoma / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. International Cooperation. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16415433.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Calaminus G, Göbel U, Schrum J, Wittkugel O, Westphal M, Timmermann B: Proton beam therapy for loco-regional control of a recurrent mixed malignant germ cell tumor of the skull in a 22-month-old girl. Klin Padiatr; 2010 May;222(3):175-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton beam therapy for loco-regional control of a recurrent mixed malignant germ cell tumor of the skull in a 22-month-old girl.
  • Recurrent CTs are often resectable only by mutilating surgery and the need for alternative treatment strategies is obvious.
  • In this situation radiation therapy is the most important treatment option for loco-regional tumor control, but bear in this area the risk of possible impairment of brain function and face deformation as long term effects.
  • CASE REPORT: In a girl with a connatal expansive growing teratoma of the skull the tumor recurred in spite of repeated surgery as mixed malignant GCT at the age of 15 months.
  • Tumor control could not be achieved with chemotherapy and additional surgery seemed not promising.
  • Therefore high dose proton beam therapy (PT) (54 Gy) has been administered to the child at the age of 22 months and led to local tumor control with only mild side effects.
  • CONCLUSION: PT treatment may be an option for specific clinical conditions in germ cell tumors where local tumor control cannot be achieved by chemotherapy and/or surgery and long lasting side effects of conventional radiotherapy due to tumor localization and age have to be considered.
  • However, PT should be implemented in treatment protocols for specific situations to guarantee supervised application, central documentation and follow-up.
  • [MeSH-major] Neoplasm Recurrence, Local / radiotherapy. Orbital Neoplasms / congenital. Orbital Neoplasms / radiotherapy. Protons / therapeutic use. Radiotherapy Planning, Computer-Assisted. Skull Base Neoplasms / congenital. Skull Base Neoplasms / radiotherapy. Teratoma / congenital. Teratoma / radiotherapy
  • [MeSH-minor] Blepharoptosis / etiology. Child, Preschool. Craniotomy. Female. Follow-Up Studies. Humans. Infant. Magnetic Resonance Imaging. Neoplasm Invasiveness. Radiation Injuries / etiology. Radiotherapy Dosage. Radiotherapy, Adjuvant. Reoperation

  • Genetic Alliance. consumer health - Malignant germ cell tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514623.001).
  • [ISSN] 1439-3824
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


6. Sioka C, Kyritsis AP: Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas. J Neurooncol; 2009 Mar;92(1):1-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas.
  • Meningioma is a common intracranial tumor, originating from the meninges of the skull or spinal canal.
  • Patients with asymptomatic small benign meningiomas can be followed without therapy, but in symptomatic patients complete surgical resection should be performed.
  • Antiprogesterone treatment can also be considered in recurrent benign meningiomas.
  • Immunotherapy with interferon-alpha and chemotherapy should be reserved for all cases of recurrent meningiomas (benign, atypical, and malignant) when all the standard therapies have failed or contraindicated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Immunotherapy / methods. Meningeal Neoplasms / therapy. Meningioma / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Clinical Trials as Topic. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2004 Jun;68(2):131-40 [15218949.001]
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):588-97 [17177201.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):271-5 [9007858.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Mar;74(3):543-7 [1346787.001]
  • [Cites] Rev Neurol. 1997 Dec;25(148):2002-5 [9528047.001]
  • [Cites] Clin Neuropathol. 2004 Jan-Feb;23(1):21-7 [14986930.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Jun;55(6):486-90 [1619417.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):508-17 [16235684.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):495-9 [15799152.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1865-74 [10815909.001]
  • [Cites] Eur J Cancer. 1991;27(11):1453-7 [1660295.001]
  • [Cites] J Clin Neurosci. 2008 Jun;15(6):721-2; author reply 722-3 [18406141.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):861-6 [2033444.001]
  • [Cites] J Neurosurg. 2007 Mar;106(3):455-62 [17367069.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):365-73; discussion 373-4 [7731518.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E10 [17961034.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):155-66 [15015781.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):133-42 [11995814.001]
  • [Cites] Gan To Kagaku Ryoho. 2007 Feb;34(2):265-8 [17301541.001]
  • [Cites] Neurochirurgie. 2004 Sep;50(4):461-7 [15547484.001]
  • [Cites] Neurology. 2007 Sep 4;69(10):969-73 [17785665.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1427-30 [15690330.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):1109-20; discussion 1120-1 [17143245.001]
  • [Cites] Eur J Cancer. 1991;27(4):416-9 [1828169.001]
  • [Cites] Skull Base. 2006 Aug;16(3):157-60 [17268588.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):165-70 [11206012.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):269-72 [8858533.001]
  • [Cites] J Neurosurg. 2000 Jul;93(1):132-5 [10883917.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):157-65 [16193387.001]
  • [Cites] Cancer Invest. 2006 Dec;24(8):727-33 [17162554.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] Hum Reprod. 1994 Jun;9 Suppl 1:202-7 [7962466.001]
  • [Cites] Clin Neurol Neurosurg. 2008 Jul;110(7):645-8 [18471956.001]
  • [Cites] Acta Neurol Scand. 1987 Jun;75(6):434-6 [2888257.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):187-92 [17525632.001]
  • [Cites] Lancet. 1995 Feb 4;345(8945):331 [7837901.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2269-76 [11489801.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):221-6 [15072471.001]
  • [Cites] Neurosurgery. 2000 Mar;46(3):692-702; discussion 702-3 [10719866.001]
  • (PMID = 19023520.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal
  • [Number-of-references] 43
  •  go-up   go-down


7. Shah JP, Gil Z: Current concepts in management of oral cancer--surgery. Oral Oncol; 2009 Apr-May;45(4-5):394-401
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surgery is the most well established mode of initial definitive treatment for a majority of oral cancers.
  • The factors that affect choice of treatment are related to the tumor and the patient.
  • The radial forearm free flap provides excellent soft tissue and lining for soft tissue defects in the oral cavity.
  • Over the course of the past thirty years there has been improvement in the overall survival of patients with oral carcinoma largely due to the improved understanding of the biology of local progression, early identification and treatment of metastatic lymph nodes in the neck, and employment of adjuvant post-operative radiotherapy or chemoradiotherapy.
  • The role of surgery in primary squamous cell carcinomas in other sites in the head and neck has evolved with integration of multidisciplinary treatment approaches employing chemotherapy and radiotherapy either sequentially or concurrently.
  • Advances in skull base surgery have significantly improved the survivorship of patients with malignant tumors of the paranasal sinuses approaching or involving the skull base.
  • Similarly, the role of the surgeon is essential throughout the life history of a patient with a malignant neoplasm in the head and neck area, from initial diagnosis through definitive treatment, post-treatment surveillance, management of complications, rehabilitation of the sequelae of treatment, and finally for palliation of symptoms.
  • [MeSH-minor] Antineoplastic Protocols. Bone Neoplasms / surgery. Combined Modality Therapy. Head and Neck Neoplasms / surgery. Humans. Patient Selection. Reconstructive Surgical Procedures. Skin Neoplasms / surgery. Skull Base Neoplasms / surgery. Soft Tissue Neoplasms / surgery. Surgical Flaps. Treatment Outcome


8. Sontheimer H: A role for glutamate in growth and invasion of primary brain tumors. J Neurochem; 2008 Apr;105(2):287-95
Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While, they share some genetic mutations with other cancers, they do present with a unique biology and have developed adaptations to meet specific biological needs.
  • Notably, glioma growth is physically restricted by the skull, and, unless normal brain cells are destroyed, tumors cannot expand.
  • It protects tumor cells from endogenously produced reactive oxygen and nitrogen species but also endows tumors with an enhanced resistance to radiation- and chemotherapy.
  • Pre-clinical data demonstrates that pharmacological inhibition of system X(c) causes GSH depletion which slows tumor growth and curtails tumor invasion in vivo.
  • An Food and Drug Administration approved drug candidate is currently being introduced into clinical trials for the treatment of malignant glioma.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9463-71 [17909056.001]
  • [Cites] J Neurosci. 2007 Jul 25;27(30):7987-8001 [17652589.001]
  • [Cites] J Neurosci. 1999 Dec 15;19(24):10767-77 [10594060.001]
  • [Cites] Cell Motil Cytoskeleton. 2000 Mar;45(3):185-99 [10706774.001]
  • [Cites] J Neurochem. 2000 May;74(5):1931-40 [10800936.001]
  • [Cites] J Membr Biol. 2000 Jul 1;176(1):31-40 [10882426.001]
  • [Cites] J Neurooncol. 2000 Mar;47(1):11-22 [10930095.001]
  • [Cites] Int J Biochem Cell Biol. 2000 Sep;32(9):931-43 [11084373.001]
  • [Cites] Prog Neurobiol. 2001 Sep;65(1):1-105 [11369436.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] Biochim Biophys Acta. 2001 Jun 6;1512(2):335-44 [11406111.001]
  • [Cites] Genes Dev. 2001 Aug 1;15(15):1913-25 [11485986.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1010-5 [11533703.001]
  • [Cites] Neurotoxicology. 2001 Oct;22(5):607-18 [11770882.001]
  • [Cites] Curr Neurol Neurosci Rep. 2001 May;1(3):217-24 [11898521.001]
  • [Cites] Nat Med. 2002 Sep;8(9):971-8 [12172541.001]
  • [Cites] Wien Klin Wochenschr. 2002 Nov 30;114(21-22):911-6 [12528323.001]
  • [Cites] NMR Biomed. 2003 Feb;16(1):12-8 [12577293.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):151-60 [12622454.001]
  • [Cites] Pediatr Clin North Am. 2004 Apr;51(2):327-57 [15062674.001]
  • [Cites] Exp Brain Res. 1971;14(1):61-76 [5157537.001]
  • [Cites] Radiat Environ Biophys. 1983;22(3):215-23 [6359235.001]
  • [Cites] Med Biol. 1984;62(2):110-4 [6471927.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 May;16(5):1289-95 [2654105.001]
  • [Cites] Neuron. 1988 Oct;1(8):623-34 [2908446.001]
  • [Cites] Science. 1991 May 10;252(5007):851-3 [1709304.001]
  • [Cites] J Neuropathol Exp Neurol. 1994 Jan;53(1):11-21 [8301315.001]
  • [Cites] N Engl J Med. 1994 Mar 3;330(9):613-22 [7905600.001]
  • [Cites] Glia. 1994 Jun;11(2):173-84 [7927645.001]
  • [Cites] Glia. 1995 Nov;15(3):211-21 [8586458.001]
  • [Cites] Glia. 1995 Nov;15(3):328-38 [8586467.001]
  • [Cites] Glia. 1995 Nov;15(3):339-47 [8586468.001]
  • [Cites] Neuron. 1996 Mar;16(3):675-86 [8785064.001]
  • [Cites] Neuron. 1996 Aug;17(2):275-85 [8780651.001]
  • [Cites] Science. 1997 Jun 13;276(5319):1699-702 [9180080.001]
  • [Cites] Eur J Neurosci. 1997 Aug;9(8):1646-55 [9283819.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):303-14 [9440027.001]
  • [Cites] J Neurovirol. 1998 Apr;4(2):204-16 [9584957.001]
  • [Cites] Neurology. 1998 May;50(5):1323-6 [9595981.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2B):1303-11 [9615807.001]
  • [Cites] J Cancer Res Clin Oncol. 1997;123(11-12):619-22 [9620220.001]
  • [Cites] J Neurobiol. 1998 Oct;37(1):110-30 [9777736.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3675-85 [9851974.001]
  • [Cites] J Biol Chem. 1999 Apr 23;274(17):11455-8 [10206947.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4383-91 [10485487.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1029-40 [10515226.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jan 14;326(2):371-7 [15582588.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):217-28 [15674479.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1934-40 [15753393.001]
  • [Cites] Cancer Biol Ther. 2004 Dec;3(12):1243-9 [15611621.001]
  • [Cites] NeuroRx. 2004 Jan;1(1):101-10 [15717010.001]
  • [Cites] J Neurosci. 2005 Aug 3;25(31):7101-10 [16079392.001]
  • [Cites] Acta Neuropathol. 2005 Nov;110(5):435-42 [16175354.001]
  • [Cites] J Neurosci. 2006 Mar 1;26(9):2458-66 [16510724.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1273-80 [16525182.001]
  • [Cites] Cell Tissue Res. 2006 May;324(2):189-202 [16609915.001]
  • [Cites] Trends Neurosci. 2007 Nov;30(11):596-602 [17950926.001]
  • (PMID = 18284616.001).
  • [ISSN] 1471-4159
  • [Journal-full-title] Journal of neurochemistry
  • [ISO-abbreviation] J. Neurochem.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS031234-13; United States / NINDS NIH HHS / NS / R01 NS052634-04; United States / NINDS NIH HHS / NS / R01 NS031234-14A1; United States / NINDS NIH HHS / NS / R01 NS036692-07; United States / NINDS NIH HHS / NS / R01 NS031234; United States / NCI NIH HHS / CA / P50 CA097247-010003; United States / NINDS NIH HHS / NS / NS031234-15; United States / NINDS NIH HHS / NS / NS036692-09A2; United States / NCI NIH HHS / CA / CA097247-010003; United States / NINDS NIH HHS / NS / R01 NS052634-03; United States / NINDS NIH HHS / NS / R01 NS036692-09A2; United States / NINDS NIH HHS / NS / R01 NS-36692; United States / NINDS NIH HHS / NS / NS031234-14A1; United States / NINDS NIH HHS / NS / NS052634-02; United States / NCI NIH HHS / CA / P50 CA097247; United States / NINDS NIH HHS / NS / R01 NS036692-08; United States / NINDS NIH HHS / NS / R01 NS-52634; United States / NINDS NIH HHS / NS / R01 NS-31234; United States / NINDS NIH HHS / NS / NS052634-03; United States / NINDS NIH HHS / NS / R01 NS052634; United States / NINDS NIH HHS / NS / R01 NS031234-15; United States / NINDS NIH HHS / NS / NS036692-07; United States / NINDS NIH HHS / NS / R01 NS052634-02; United States / NINDS NIH HHS / NS / NS036692-08; United States / NINDS NIH HHS / NS / NS031234-13; United States / NINDS NIH HHS / NS / R01 NS036692; United States / NCI NIH HHS / CA / P50-CA97247; United States / NINDS NIH HHS / NS / NS052634-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amino Acid Transport System X-AG; 0 / Antineoplastic Agents; 3KX376GY7L / Glutamic Acid; 48TCX9A1VT / Cystine
  • [Number-of-references] 59
  • [Other-IDs] NLM/ NIHMS67017; NLM/ PMC2557065
  •  go-up   go-down


9. Udelnow A, Leinung S, Dannenberg C, Trantakis Ch, Schober R, Schönfelder M, Würl P: [A giant malignant tumour of the skull-Case report and differential diagnosis]. Zentralbl Chir; 2002 Mar;127(3):243-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A giant malignant tumour of the skull-Case report and differential diagnosis].
  • The patient remembered a mastectomy and axillary lymphadenectomy followed by chemotherapy and radiation 8 years ago.
  • The tumor described here can be identified as a metastasis of this rare neoplasm.
  • [MeSH-major] Breast Neoplasms / diagnosis. Phyllodes Tumor / secondary. Skull Neoplasms / secondary
  • [MeSH-minor] Aged. Craniotomy. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Parietal Lobe / pathology. Parietal Lobe / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11935491.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Arndt S, Echternach M, Aschendorff A, Schipper J, Maier W: [Malignant rhino- and otobasal mucosal melanomas--therapy and outcome]. Laryngorhinootologie; 2008 Jun;87(6):412-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant rhino- and otobasal mucosal melanomas--therapy and outcome].
  • BACKGROUND: Malignant melanoma of the rhinobasal mucosa is very rare and makes up less than one percent of all malignant melanomas.
  • During the past two decades, a variety of therapeutic modalities has been proposed.
  • MATERIALS AND METHODS: In a retrospective quality assessment, we analysed the charts of fifteen consecutive patients suffering from malignant melanoma of the skull base who where treated in our department since 1993.
  • The influence of specific surgical and adjuvant therapy on recurrence and outcome was evaluated.
  • All patients underwent surgery as the initial treatment, in 8 cases followed by adjuvant therapy.
  • CONCLUSION: We conclude from our data and analysis of literature that the prognosis of MM has not developed favourably during the past two decades.
  • Radiation therapy and adjuvant immuno- or chemotherapy seems to have a positive impact.
  • [MeSH-major] Melanoma / surgery. Nose Neoplasms / surgery. Palatal Neoplasms / surgery. Paranasal Sinus Neoplasms / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Interferon-alpha / therapeutic use. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Orbit Evisceration. Palliative Care. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18506652.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Interferon-alpha
  •  go-up   go-down


11. Sakuma I, Tomura N, Omachi K, Takahashi S, Watarai J, Sasajima T, Mizoi K: [A case of astrocytoma with extracranial extension after malignant transformation]. No To Shinkei; 2003 Feb;55(2):153-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of astrocytoma with extracranial extension after malignant transformation].
  • A case of astrocytoma with extracranial extension after malignant transformation is presented.
  • The initial diagnosis was made as low-grade astrocytoma.
  • After surgery, chemotherapy and radiotherapy were performed.
  • The tumor invades the skull base and extended into the infratemporal fossa 25 months after surgery.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Glioblastoma / pathology. Skull Base Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12684996.001).
  • [ISSN] 0006-8969
  • [Journal-full-title] Nō to shinkei = Brain and nerve
  • [ISO-abbreviation] No To Shinkei
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Selesnick SH, Burt BM: Regional spread of nonneurogenic tumors to the skull base via the facial nerve. Otol Neurotol; 2003 Mar;24(2):326-33
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regional spread of nonneurogenic tumors to the skull base via the facial nerve.
  • Five patients received adjuvant radiation, and two received adjuvant radiation and chemotherapy.
  • Perineural spread was histologically found in all cases of malignant disease.
  • Four patients had unresectable malignant disease, and two died despite multimodality therapy.
  • CONCLUSIONS: The facial nerve provides a route for the spread of neoplastic disease into the temporal bone, and perineural invasion is an important mechanism of invasion and motility of malignant disease.
  • [MeSH-major] Carcinoma / pathology. Cranial Nerve Neoplasms / pathology. Facial Nerve / pathology. Parotid Neoplasms / pathology. Skull Base Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Child. Female. Gadolinium. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness / pathology. Radiopharmaceuticals. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12621352.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


13. Ganly I, Patel SG, Singh B, Kraus DH, Bridger PG, Cantu G, Cheesman A, De Sa G, Donald P, Fliss DM, Gullane P, Janecka I, Kamata SE, Kowalski LP, Levine PA, Medina Dos Santos LR, Pradhan S, Schramm V, Snyderman C, Wei WI, Shah JP: Craniofacial resection for malignant paranasal sinus tumors: Report of an International Collaborative Study. Head Neck; 2005 Jul;27(7):575-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Craniofacial resection for malignant paranasal sinus tumors: Report of an International Collaborative Study.
  • BACKGROUND: Malignant tumors of the superior sinonasal vault are rare, and, because of this and the varied histologic findings, most outcomes data reflect the experience of small patient cohorts.
  • One hundred eighty-eight patients (56.3%) had had prior single-modality or combined treatment, which included surgery in 120 (36%), radiation in 79 (23.7%), and chemotherapy in 56 (16.8%).
  • Adjuvant radiotherapy was given in 161 (48.2%) and chemotherapy in 16 (4.8%).
  • Statistical analyses for outcomes were performed in relation to patient characteristics, tumor characteristics, including histologic findings and extent of disease, surgical resection margins, prior radiation, and prior chemotherapy to determine predictive factors.
  • CONCLUSIONS: CFR for malignant paranasal sinus tumors is a safe surgical treatment with an overall mortality of 4.5% and complication rate of 33%.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Paranasal Sinus Neoplasms / surgery. Skull / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cohort Studies. Female. Follow-Up Studies. Humans. International Cooperation. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Postoperative Complications. Skull Base / pathology. Skull Base / surgery. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15825201.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


14. Katz TS, Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Villaret DB: Malignant tumors of the nasal cavity and paranasal sinuses. Head Neck; 2002 Sep;24(9):821-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant tumors of the nasal cavity and paranasal sinuses.
  • PURPOSE: To evaluate the role of radiation therapy in patients with nasal cavity and paranasal sinus tumors.
  • MATERIALS AND METHODS: Between October 1964 and July 1998, 78 patients with malignant tumors of the nasal cavity (48 patients), ethmoid sinus (24 patients), sphenoid sinus (5 patients), or frontal sinus (1 patient) were treated with curative intent by radiation therapy alone or in the adjuvant setting.
  • Forty-seven patients were treated with irradiation alone, 25 with surgery and postoperative irradiation, 2 with preoperative irradiation and surgery, and 4 with chemotherapy in combination with irradiation with or without surgery.
  • RESULTS: The 5-year actuarial local control rate for stage I (limited to the site of origin; 22 patients) was 86%; for stage II (extension to adjacent sites (eg, adjacent sinuses, orbit, pterygomaxillary fossa, nasopharynx; 21 patients) was 65%; and for stage III (destruction of skull base or pterygoid plates, or intracranial extension; 35 patients) was 34%.
  • Of the 67 (86%) patients who were initially seen with node-negative disease, 39 (58%) received no elective neck treatment, and 28 (42%) received elective neck irradiation.
  • Of the 39 patients who received no elective neck treatment, 33 (85%) did not experience recurrence in the neck compared with 25 (89%) of 28 patients who received elective neck irradiation.
  • CONCLUSION: Surgery and postoperative radiation therapy may result in improved local control, absolute survival, and complications when compared with radiation therapy alone.
  • [MeSH-major] Carcinoma / therapy. Nasal Cavity. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blindness / etiology. Blindness / prevention & control. Cause of Death. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Staging. Osteoradionecrosis / etiology. Postoperative Care. Preoperative Care. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Risk Factors. Survival Rate. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley Periodicals, Inc. Head Neck 24: 821-829, 2002
  • (PMID = 12211046.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Minovi A, Basten O, Hunter B, Draf W, Bockmühl U: Malignant peripheral nerve sheath tumors of the head and neck: management of 10 cases and literature review. Head Neck; 2007 May;29(5):439-45
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumors of the head and neck: management of 10 cases and literature review.
  • BACKGROUND: This study analyzes the management and outcomes of a series of 10 malignant peripheral nerve sheath tumors (MPNST) of the head and neck.
  • METHODS: From 1984 to 2004, 10 patients underwent surgical treatment of a MPNST.
  • RESULTS: Eight tumors were located at the lateral skull base; 2 involved the vagus nerve in isolation.
  • Complete tumor removal is the mainstay of treatment and most important prognostic factor of MPNST.
  • The role of adjuvant chemotherapy remains controversial.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / therapy. Neoplasm Recurrence, Local / mortality. Nerve Sheath Neoplasms / mortality. Nerve Sheath Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley Periodicals, Inc.
  • (PMID = 17163467.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


16. Hammond RR, Duggal N, Woulfe JM, Girvin JP: Malignant transformation of a dysembryoplastic neuroepithelial tumor. Case report. J Neurosurg; 2000 Apr;92(4):722-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of a dysembryoplastic neuroepithelial tumor. Case report.
  • Computerized tomography (CT) scanning revealed a superficial hypodense nonenhancing lesion in the midleft frontal convexity, with some remodeling of the overlying skull.
  • He received no chemotherapy or radiation therapy and remained well for 11 years.
  • A Grade IV astrocytoma was resected, and within the malignant tumor was a superficial area reminiscent of a dysembryoplastic neuroepithelial tumor (DNT).
  • This case is the first documented example of malignant transformation of a DNT.
  • It serves as a warning of the potential for malignant transformation in this entity, which has been traditionally accepted as benign.
  • [MeSH-minor] Adult. Astrocytoma / pathology. Electroencephalography. Epilepsies, Partial / diagnosis. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local / pathology. Neuroglia / pathology. Neurons / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Dysembryoplastic Neuroepithelial Tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10761668.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


17. Hormozi AK, Ghazisaidi MR, Hosseini SN: Unusual presentation of peripheral primitive neuroectodermal tumor of the maxilla. J Craniofac Surg; 2010 Nov;21(6):1761-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The peripheral primitive neuroectodermal tumor (pPNET) is a rare and highly malignant soft tissue neoplasm in children and young adults.
  • Two years after diagnosis, she experienced diplopia, and then magnetic resonance imaging was done, which showed a mass in the optic chiasma and parasellar region.
  • The typical appearance resembled large noncalcified soft tissue masses in the magnetic resonance image and computed tomographic scan of the maxilla.
  • Diagnosis was established by immunohistochemical features.
  • She was treated with surgery, chemotherapy, radiation therapy, and gamma knife.
  • [MeSH-major] Maxillary Neoplasms / diagnosis. Neuroectodermal Tumors, Primitive, Peripheral / diagnosis
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Neoadjuvant Therapy. Neoplasm Recurrence, Local / pathology. Optic Chiasm / pathology. Optic Nerve Neoplasms / secondary. Radiosurgery. Radiotherapy, Adjuvant. Sella Turcica / pathology. Skull Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119416.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Feiz-Erfan I, Han PP, Spetzler RF, Lanzino G, Ferreira MA, Gonzalez LF, Porter RW: Salvage of advanced squamous cell carcinomas of the head and neck: internal carotid artery sacrifice and extracranial-intracranial revascularization. Neurosurg Focus; 2003 Mar 15;14(3):e6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Squamous cell carcinoma (SCC) of the head and neck may involve the carotid artery (CA) in the neck or skull base.
  • METHODS: Records obtained in five consecutive patients (three men, and two women; mean age 58 years, range 47-69 years) treated for recurrent or progressive SCC involving the internal carotid artery (ICA) at the skull base were reviewed retrospectively.
  • CONCLUSIONS: A high rate of morbidity and mortality is associated with cases in which skull base CA sacrifice and an EC-IC bypass are performed.
  • Not all resected arteries are shown to have malignant infiltration on histological examination.
  • Better preoperative imaging criteria are needed to define malignant infiltration of the ICA at the skull base.
  • Chemotherapy and radiotherapy without aggressive tumor resection may be an option for these patients.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Carotid Artery, Internal / surgery. Cerebral Revascularization / methods. Head and Neck Neoplasms / surgery. Salvage Therapy
  • [MeSH-minor] Aged. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Postoperative Complications / etiology. Preoperative Care. Saphenous Vein / transplantation. Skull Base. Stroke / etiology. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709723.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Oskouian RJ Jr, Jane JA Sr, Dumont AS, Sheehan JM, Laurent JJ, Levine PA: Esthesioneuroblastoma: clinical presentation, radiological, and pathological features, treatment, review of the literature, and the University of Virginia experience. Neurosurg Focus; 2002 May 15;12(5):e4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esthesioneuroblastoma: clinical presentation, radiological, and pathological features, treatment, review of the literature, and the University of Virginia experience.
  • Esthesioneuroblastoma is a rare and malignant upper nasal cavity neoplasm involving the anterior skull base.
  • Treatment includes surgery, radiotherapy, chemotherapy, or a combination.
  • The ideal treatment modality has yet to be determined.
  • Management strategies for this neoplasm lack uniformity, and there is no universally accepted staging system.
  • In this paper the authors discuss the clinical presentation, radiological and pathological features, and treatment of this rare, malignant skull base neoplasm, as well as review the literature.
  • They also present their results and treatment regimen, which includes preoperative radio- and chemotherapy or 1) craniofacial resection if the lesion has a significant intracerebral component, or 2) frontal sinus resection if little intracranial extension exists.
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Postoperative Complications. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16119902.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 71
  •  go-up   go-down


20. Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE: Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg; 2002 Aug;97(2):341-6
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: The management of certain meningiomas of the skull base and those involving the dural venous sinuses remains a challenge.
  • In recent reports it has been suggested that hydroxyurea chemotherapy can cause regression of unresectable and recurrent meningiomas.
  • The authors report their experience in using hydroxyurea for the treatment of patients with recurrent or unresectable meningiomas.
  • In 16 patients the meningiomas were benign, in three they had atypical features, and in one the meningioma was malignant.
  • Four patients with benign meningiomas had previously received radiotherapy (two were treated with conventional fractionated radiotherapy and two with stereotactic radiosurgery), three with atypical meningiomas received conventional fractionated radiotherapy, and the one with a malignant meningioma received conventional radiotherapy with additional stereotactic radiosurgery.
  • Tumor enlargement was documented in all patients on neuroimages obtained before initiation of hydroxyurea therapy.
  • All patients were evaluable for response to therapy.
  • In 12 patients with benign meningiomas, the disease had stabilized on neuroimages obtained posttreatment (median duration of treatment 122 weeks, range 8-151 weeks), and two of these showed clinical improvement.
  • One patient with a benign meningioma experienced a minor partial response that was noted after 39 weeks of treatment and was confirmed on neuroimaging and clinical evaluations.
  • In the patient with a malignant meningioma, progression was confirmed on neuroimages obtained at 24 weeks.
  • Hydroxyurea has been reasonably well tolerated, although one patient discontinued therapy because of moderate myelosuppression.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Disease Progression. Hydroxyurea / therapeutic use. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / physiopathology. Meningioma / drug therapy. Meningioma / physiopathology. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / physiopathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Karnofsky Performance Status. Male. Middle Aged. Remission Induction. Severity of Illness Index. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12186462.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


21. Ganly I, Gross ND, Patel SG, Bilsky MH, Shah JP, Kraus DH: Outcome of craniofacial resection in patients 70 years of age and older. Head Neck; 2007 Feb;29(2):89-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seventeen (47%) patients had had prior single-modality or combined treatment, which included surgery in 14 (40%), radiation in 13 (36%), and chemotherapy in 2 (6%).
  • Thirty-five patients had a malignant tumor and 1 patient a benign tumor; 15 (42%) had high-grade, 17 (47%) intermediate-grade, and 4 (11%) low-grade pathology.
  • Adjuvant radiotherapy was given in 15 (42%) and chemotherapy in 1 (3%).
  • [MeSH-major] Nose Neoplasms / surgery. Postoperative Complications. Salivary Gland Neoplasms / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Carcinoma / mortality. Carcinoma / pathology. Carcinoma / surgery. Cranial Fossa, Anterior / surgery. Cranial Fossa, Middle / surgery. Databases as Topic. Esthesioneuroblastoma, Olfactory / mortality. Esthesioneuroblastoma, Olfactory / pathology. Esthesioneuroblastoma, Olfactory / surgery. Female. Follow-Up Studies. Humans. Male. Melanoma / mortality. Melanoma / pathology. Melanoma / surgery. Neoplasm Recurrence, Local. Prospective Studies. Surgical Flaps. Survival Analysis


22. Daw NC, Mahmoud HH, Meyer WH, Jenkins JJ, Kaste SC, Poquette CA, Kun LE, Pratt CB, Rao BN: Bone sarcomas of the head and neck in children: the St Jude Children's Research Hospital experience. Cancer; 2000 May 1;88(9):2172-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: There were 10 males and 18 females (median age, 12.6 years) each with a single sarcoma: osteosarcoma (18), Ewing sarcoma (7), malignant fibrous histiocytoma (MFH) (2), and fibrosarcoma (1).
  • Primary tumor sites included the maxilla (13), skull (10), mandible (2), and other sites (3).
  • All but one patient with Ewing sarcoma had localized disease at the time of diagnosis.
  • All patients underwent surgery: complete resection, 8; gross total resection, 4; incomplete resection, 14; and biopsy only, 2; 22 also received chemotherapy.
  • Twelve patients survived a median of 8.4 years after diagnosis, 14 died of disease, and 2 died of unrelated causes.
  • Local disease progression was evident in 12 patients (9 with osteosarcoma, 2 with MFH, and 1 with Ewing sarcoma) who died of disease, 9 of whom had the initial treatment of biopsy alone or incomplete resection.
  • Patients with osteosarcoma who had the initial treatment of incomplete resection or biopsy alone were more likely to experience local failure (P = 0.001) and had poorer survival (P = 0.014) than those who underwent complete or gross total resection.
  • CONCLUSIONS: Bone sarcomas of the head and neck are rare among children and most often are localized at the time of diagnosis.
  • Although aggressive surgery is essential for the cure of osteosarcoma, its necessity in the treatment of Ewing sarcomas remains controversial.
  • [MeSH-major] Sarcoma / surgery. Skull Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Cause of Death. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease Progression. Female. Fibrosarcoma / surgery. Histiocytoma, Benign Fibrous / surgery. Hospitals, Pediatric. Humans. Infant. Male. Mandibular Neoplasms / surgery. Maxillary Neoplasms / surgery. Neoplasm Recurrence, Local / pathology. Osteosarcoma / surgery. Radiotherapy, Adjuvant. Retrospective Studies. Sarcoma, Ewing / surgery. Survival Rate. Tennessee. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10813731.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / CA-23099
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  •  go-up   go-down


23. Li Y, Zhang TM, An YZ, Shi JT, Fu JD, Qiu E: [Clinical study of lacrimal gland tumor involving anterior and middle cranial fossae]. Zhonghua Yi Xue Za Zhi; 2006 Jun 20;86(23):1597-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinical manifestations of lacrimal gland tumor involving the anterior and middle cranial fossae and the effect of transcranial-orbital approach in treatment of such tumor.
  • METHODS: A retrospective study was conducted on the clinical data of 23 cases lacrimal gland tumor involving the anterior and middle cranial fossae confirmed by radiological examination, including 11 cases of adenoid cystic carcinoma, 6 cases of pleomorphic adenocarcinoma (malignant mixed tumor), 2 cases of adenocarcinoma, 1 case of squamous cell carcinoma, 1 case of ductal carcinoma, 1 case of mucoepidermoid carcinoma, and 1 case of benign mixed tumor, 15 males and 8 females, aged 42.5 (2 - 76), with a case history of 43 months (2 months to 27 years), with the chief complaints of progressive proptosis, disgenesia of the eye ball, and orbit pain, all undergoing transcranial-orbital operation from August 1998 to February. 2006.
  • CONCLUSIONS: Malignant lacrimal gland tumors, mainly adenoid cystic carcinomas, incline to involve the anterior and middle cranial fossae.
  • Suitable treatment strategy should by combination of operation with irradiation or chemotherapy.
  • [MeSH-major] Eye Neoplasms / pathology. Lacrimal Apparatus / pathology. Skull Base Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Cranial Fossa, Anterior. Cranial Fossa, Middle. Craniotomy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16854296.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


24. Proulx DR, Ruslander DM, Dodge RK, Hauck ML, Williams LE, Horn B, Price GS, Thrall DE: A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. Vet Radiol Ultrasound; 2003 May-Jun;44(3):352-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the early notion that canine oral malignant melanoma is radioresistant, recent data suggest that external beam radiotherapy is effective in local tumor control.
  • The role of chemotherapy in the management of canine oral melanoma has also not been determined.
  • (1) to compare the efficacy of three radiation therapy protocols (36 Gy, 9 Gy x 4 fractions; 30 Gy, 10 Gy x 3 fractions; or >45 Gy, 2-4 Gy x 12-19 fractions) for the treatment of dogs with oral malignant melanoma, (2) to identify any host or tumor factors influencing prognosis, and (3) to determine the impact of systemic chemotherapy on treatment outcome.
  • Information regarding response to therapy, disease progression, and survival were determined from the medical records or from information obtained by telephone or mail survey.
  • Relationships between host, tumor, and treatment variables and outcome measures (response, time to first event, and survival) were evaluated using Fisher's exact test (response) and the Cox regression model (time to first event and survival).
  • The median time to first event for the 140 dogs was 5.0 months (95% C.I., 4-6 months) and the median survival was 7.0 months (95% C.I., 6-9 months).
  • In the univariate analysis, the following variables were associated with increased time to first event and survival:.
  • (2) lack of bone lysis observed on skull imaging, and (3) microscopic tumor burden.
  • In a multivariate analysis of 111 dogs with complete data for these variables, tumor sublocation, bone lysis, and tumor volume were identified as joint predictors of time to first event (p < .001, p < .001, and p = .04, respectively) and survival (p < .001, p < .001, and p = .05, respectively).
  • There were no differences in response, time to first event and survival between the three radiation therapy protocols used.
  • Systemic chemotherapy had no impact on the development of metastatic disease, time to first event, or survival, although the dosages used in this study were suboptimal.
  • External beam radiation therapy is effective in local disease control of canine oral malignant melanoma; however, the optimal fractionation scheme has yet to be determined.
  • The high metastatic rate observed with this disease and the inefficacy of systemic chemotherapy indicate that further investigation into novel therapies is warranted.
  • [MeSH-major] Dog Diseases / mortality. Melanoma / veterinary. Mouth Neoplasms / veterinary. Neoplasm Recurrence, Local / veterinary
  • [MeSH-minor] Animals. Disease-Free Survival. Dogs. Dose Fractionation. Female. Male. North Carolina / epidemiology. Records as Topic / veterinary. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12816381.001).
  • [ISSN] 1058-8183
  • [Journal-full-title] Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association
  • [ISO-abbreviation] Vet Radiol Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Hanna E, DeMonte F, Ibrahim S, Roberts D, Levine N, Kupferman M: Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol Head Neck Surg; 2009 Dec;135(12):1219-24
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS: All patients with biopsy-proved malignant neoplasm of the sinonasal region who were treated with endoscopic resection between 1992 and 2007 were included in the study, and their charts were reviewed for demographics, histopathologic findings, treatment details, and outcome.
  • Of the 120 patients, 41% presented with previously untreated disease, 46% presented with persistent disease that had been partially resected, and 13% presented with recurrent disease after prior treatment.
  • Tumors extended to or invaded the skull base in 20% and 11% of the patients, respectively.
  • An intracranial epicenter (P < .001) and extension to (P = .001) or invasion of (P < .001) the skull base were significantly more common in patients treated with CEA than in those treated with EEA.
  • The most common tumor types were esthesioneuroblastoma (17%), sarcoma (15%), adenocarcinoma (14%), melanoma (14%), and squamous cell carcinoma (13%).
  • Of the 120 patients, 50% were treated with surgery alone, 37% received postoperative radiation therapy, and 13% were treated with surgery, radiation therapy, and chemotherapy.
  • CONCLUSIONS: To the best of our knowledge, this is the largest US series to date of patients with malignant tumors of the sinonasal tract treated with endoscopic resection.
  • Our results suggest that, in well-selected patients and with appropriate use of adjuvant therapy, endoscopic resection of sinonasal cancer results in acceptable oncologic outcomes.
  • [MeSH-minor] Adenocarcinoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Child. Craniotomy. Disease-Free Survival. Esthesioneuroblastoma, Olfactory / surgery. Ethmoid Sinus. Female. Humans. Male. Melanoma / surgery. Middle Aged. Neoplasm Recurrence, Local. Nose Neoplasms / mortality. Nose Neoplasms / surgery. Radiotherapy, Adjuvant. Retrospective Studies. Sarcoma / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026819.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Issing PR, Hemmanouil I, Wilkens L, Karstens H, Lenarz T: [Long term results in adenoidcystic carcinoma]. Laryngorhinootologie; 2002 Feb;81(2):98-105
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common symptoms were a tumor-related swelling and pain which persisted for a duration of several months after final diagnosis could be established.
  • No definitive differentiation was possible in 10 specimens.
  • The skull base was infiltrated in 16 patients.
  • Except one patient all 54 underwent surgical therapy.
  • Postoperative radiotherapy was additionally given in 25 cases which was combined with a chemotherapy in 6 patients.
  • Lymphnode metastases were observed in 13 patients after a latency of 3.3 years in average, but predominantly pulmonary metastases as distant spread developed in 18 patients after 5.8 years significantly later.
  • Male sex, infiltration of the skull base and histological evidence of perineural and perivascular spread proved to be statistically significant factors for an unfavourable prognosis.
  • CONCLUSIONS: Due to the uncommon biological behaviour with a slow growth on the one hand side and an aggressive local invasion on the other hand side the ACC can be regarded as a challenging malignant disease for the clinician whose adequate therapy does not allow any standardized regime.
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Laryngeal Neoplasms / diagnosis. Laryngeal Neoplasms / surgery. Laryngeal Neoplasms / therapy. Lymphatic Metastasis. Male. Middle Aged. Nasopharyngeal Neoplasms / diagnosis. Nasopharyngeal Neoplasms / surgery. Nasopharyngeal Neoplasms / therapy. Neoplasm Recurrence, Local. Parotid Neoplasms / diagnosis. Parotid Neoplasms / surgery. Parotid Neoplasms / therapy. Prognosis. Retrospective Studies. Submandibular Gland. Time Factors

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11914946.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


27. Marosi C, Hassler M, Roessler K, Reni M, Sant M, Mazza E, Vecht C: Meningioma. Crit Rev Oncol Hematol; 2008 Aug;67(2):153-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five-year survival for typical meningiomas exceeds 80%, but is poorer (5-year survival <60%) in malignant and atypical meningiomas.
  • Complete surgical excision is the standard treatment.
  • Radiotherapy is currently used in the clinical practice in atypical, malignant or recurrent meningioma at a total dose of 45-60Gy.
  • Radiosurgery has gained more and more importance in the management of meningiomas, especially in meningiomas that cannot be completely resected as for many skull base meningiomas.
  • Medical therapy for patients with recurrent, progressive and symptomatic disease after repeated surgery, radiosurgery and radiotherapy is investigational.
  • Hormonal therapy with progesterone antagonists has shown modest results, while chemotherapy with hydroxyurea appears moderately active.
  • [MeSH-major] Meningeal Neoplasms / therapy. Meningioma / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Staging. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342535.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 184
  •  go-up   go-down


28. Chuang SS, Lin CN, Li CY: Primary bony peripheral T-cell lymphoma mimicking nasal type NK/T-cell lymphoma: a case report. Pathol Res Pract; 2002;198(5):369-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bony peripheral T-cell lymphoma mimicking nasal type NK/T-cell lymphoma: a case report.
  • Natural killer (NK)/T-cell lymphomas are highly aggressive lymphomas of NK- or T-cell lineage with predominant extranodal presentation and are divided into nasal and nasal-type (extra-nasal).
  • We report a primary bony peripheral T-cell lymphoma mimicking NK/T-cell lymphoma, nasal type.
  • A 22-year-old Taiwanese male presented with a frontal skull bone mass noted for 3 weeks, and received craniectomy with tumor removal.
  • Polymerase chain reaction study of formalin-fixed tissue showed clonal rearrangement of the T-cell receptor-gamma chain gene.
  • The diagnosis was peripheral T-cell lymphoma, unspecified subtype.
  • His lymphoma was refractory to chemotherapy, and bony metastases developed in the right iliac bone 2 months later.
  • We emphasize the importance of detailed immunohistochemical and gene rearrangement studies for the classification of malignant lymphomas via a very rare primary bony lymphoma of peripheral T-cell subtype.
  • [MeSH-minor] Adult. Antigens, CD / analysis. Biomarkers, Tumor / analysis. Clone Cells. DNA, Neoplasm / genetics. Diagnosis, Differential. Fatal Outcome. Frontal Bone / pathology. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics. Humans. Male. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12092774.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


29. Gadwal SR, Fanburg-Smith JC, Gannon FH, Thompson LD: Primary chondrosarcoma of the head and neck in pediatric patients: a clinicopathologic study of 14 cases with a review of the literature. Cancer; 2000 May 1;88(9):2181-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumors most frequently involved the maxillary sinus (n=4), followed by the mandible (n=3), nasal cavity (n=2), and neck (n=2), with 1 each of the nasopharynx, orbit, and base of the skull.
  • All tumors were invasive and malignant as determined by radiology and/or histology.
  • All patients were treated by surgery, followed by radiation (n=5) and/or chemotherapy (n=2).
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Headache / diagnosis. Humans. Male. Mandibular Neoplasms / pathology. Maxillary Sinus Neoplasms / pathology. Nasal Obstruction / diagnosis. Neoplasm Invasiveness. Nose Neoplasms / pathology. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Rhinitis / diagnosis. Sinusitis / diagnosis

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10813732.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 41
  •  go-up   go-down


30. Farias TP, Dias FL, Lima RA, Kligerman J, de Sá GM, Barbosa MM, Gonçalves FB Jr: Prognostic factors and outcome for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg; 2003 Jul;129(7):794-9
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Nasopharyngeal cancer (NPC) is a distinct form of cancer of the upper respiratory or digestive tract in which the epidemiologic features, origin, histopathologic types, treatment, and prognosis are different from those associated with other malignant neoplasms of this anatomical area.
  • Recent publications have demonstrated the advantage of aggressive multimodality treatment for advanced NPC.
  • OBJECTIVES: To evaluate the results of standardized treatment of NPC during 11 years and to identify pertinent factors for clinical outcome.
  • Documented data of the initial presenting symptoms, head and neck examination, radiotherapy protocols, chemotherapy regimens, and surgical technique were analyzed.
  • To determine important prognostic factors, we correlated survival rates with age, clinical stage, tumor extent, histopathological type, and therapeutic approach.
  • Gross extension of the primary tumor involving the facial bones and skull base was observed in 39.3% and 20.8%, respectively.
  • Just under 75% of patients were treated with radiotherapy (median dose, 6600 cGy), and 25.4% underwent concomitant chemoradiotherapy with adjuvant chemotherapy (cisplatin plus 5-fluorouracil) (median dose, 6800 cGy).
  • The disease-specific survival for the radiotherapy group was 22.5%, compared with 61.4% for the chemoradiotherapy plus adjuvant chemotherapy group (P =.004).
  • Factors associated with adverse outcomes were age older than 40 years at treatment (P =.001), advanced TNM stage (P =.002), skull base invasion (P =.004), and facial bone invasion (P<.001).
  • CONCLUSIONS: Compared with radiotherapy alone, concomitant chemoradiotherapy with adjuvant chemotherapy improved the treatment outcome of patients with NPC treated in our institution.
  • [MeSH-major] Nasopharyngeal Neoplasms / mortality. Nasopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Brachytherapy. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12874084.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Vergani F, Pirola E, Fiori L, Pagni F, Parmigiani F, Sganzerla EP: Combined transcranial and endoscopic nasal resection for esthesioneuroblastoma. Technical note. J Neurosurg Sci; 2007 Jun;51(2):99-102
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Esthesioneuroblastoma is a rare malignant neoplasm arising in the nasal cavity.
  • We describe the case of a young male presenting with a large esthesioneuroblastoma involving the nasal cavity and the anterior cranial fossa, causing a huge skull base destruction.
  • The operative technique is reviewed in detail, along with the method used for the reconstruction of the anterior skull base defect.
  • [MeSH-minor] Adult. Blood Coagulation Disorders. Cranial Sinuses / pathology. Craniotomy / methods. Ethmoid Bone / pathology. Ethmoid Bone / surgery. Humans. Magnetic Resonance Imaging. Male. Nasal Septum / surgery. Nasal Septum / transplantation. Olfactory Mucosa / pathology. Postoperative Hemorrhage / drug therapy. Postoperative Hemorrhage / prevention & control. Reconstructive Surgical Procedures / methods. Surgical Flaps. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17571044.001).
  • [ISSN] 0390-5616
  • [Journal-full-title] Journal of neurosurgical sciences
  • [ISO-abbreviation] J Neurosurg Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down






Advertisement